Side effects can happen with any type of treatment, but everyones experience is different. Some people may have many side effects. Others have fewer.
Side effects can happen any time during, immediately after or days to months after a stem cell transplant. Short-term (acute) side effects generally develop during the first 100 days after a stem cell transplant. Long-term (chronic) side effects generally develop 100 or more days after the transplant. Most side effects go away on their own or can be treated, but some side effects can last a long time or become permanent.
Side effects of a stem cell transplant will depend mainly on:
A stem cell transplant is very complex. It can take 6 to 12 months or longer for your blood counts to be back to normal and your immune system to work well. Side effects of a stem cell transplant can be very serious or even life-threatening. The healthcare team will watch you closely during this time. They will take measures to prevent side effects and will quickly deal with any side effects that develop.
Children usually have less severe side effects than adults and will often recover from them faster. But its hard to say exactly which side effects a child will have, how long they will last and when the child will recover.
Many common side effects, such as nausea, vomiting, fatigue and temporary hair loss, are from the chemotherapy or radiation therapy given before the transplant. Other side effects are related to the stem cell transplant.
You will have low blood cells counts after a stem cell transplant. It takes time for stem cells to make their way to the bone marrow and start making new blood cells (called engraftment).
You will have daily blood tests to check the number of different types of blood cells until doctors see a steady increase in blood cell counts.
Infection is one of the most common early side effects of a stem cell transplant. It happens because the white blood cell count is very low and the immune system is weak. Bacterial infections are most common. Viral or fungal infections can also happen.
The risk of infection for all types of transplant is high until the bone marrow starts to make white blood cells. The risk is highest after an allogeneic transplant because you may be taking medicines to suppress the immune system to prevent graft-versus-host disease (GVHD).
Infection can also happen a long time after a stem cell transplant. The risk of late infection depends on how quickly your immune system recovers, whether you have GVHD and if you are taking medicines to suppress your immune system.
Fever is often the first sign of infection. Even if there is no sign of infection, most people are given medicines to prevent infection until their white blood cell counts start to rise. Doctors may also prescribe a colony-stimulating factor (CSF) such as filgrastim (Neupogen) following a stem cell transplant to help lower the risk of infection and speed up the process of making new blood cells.
Bleeding can happen after a stem cell transplant because the platelet count is very low and it reduces the bloods ability to clot. Some people get serious bleeding problems (hemorrhage). If the red blood cell count is too low, it can lead to anemia. You may need platelet transfusions until the transplanted stem cells start to work, especially during the first month after the transplant.
Anemia is a low red blood cell count and a lower concentration of hemoglobin in blood cells. Hemoglobin is the part of the red blood cell that carries oxygen. When hemoglobin levels are low, body tissues dont get enough oxygen and cant work properly. Colony-stimulating factors, such as epoetin alfa (Eprex, erythropoietin) or darbepoetin (Aranesp), may be given to help increase red blood cell counts. If the red blood cell count is too low, blood transfusions may be needed.
Graft-versus-host disease (GVHD) might happen after an allogeneic stem cell transplant. Healthy stem cells from the donor (person who gives the stem cells) attack the cells of the recipient (person receiving the stem cells). The cells from the donor see the recipients cells as foreign and start to destroy them. GVHD can permanently damage an organ.
You may have to take immune-suppressing drugs for months or years after an allogeneic transplant to prevent or treat GVHD.
Veno-occlusive disease (VOD) happens when small blood vessels that lead to the liver become blocked. VOD is more common after an allogeneic transplant. It can develop in the first few weeks after a stem cell transplant and can lead to liver damage.
Symptoms include jaundice, tenderness of the liver and fluid buildup in the abdomen. Medicine may be used to prevent or treat VOD.
Digestive problems happen because tissues in the mouth, stomach and intestines are sensitive to the chemotherapy drugs given before the transplant. Digestive problems can also be caused by infection, GVHD or side effects of medicines.
Digestive system problems include:
Your healthcare team may give you special mouthwashes or lozenges and pain medicines for a sore mouth. They will also talk to you about good mouth care during and after treatment. You may have medicines to control diarrhea, nausea and vomiting.
If you have trouble eating, the healthcare team may suggest that you eat small meals and snacks instead of big meals or take food supplements.
For severe eating problems, you may be given nutrition through the central venous catheter (tube). This is called parenteral nutrition or total parenteral nutrition (TPN).
The therapy given before the transplant and GVHD can cause skin problems. This side effect is common when certain chemotherapy drugs and total body irradiation (TBI) are used. Skin problems include rashes, itching, blisters and peeling skin. The healthcare team will tell you how to care for your skin. Medicated creams or ointments and other medicines may be given to help manage skin problems.
Temporary hair loss can also happen after therapies given before the transplant. Hair loss is rarely permanent. It usually grows back within 3 to 6 months after the transplant.
Pain occurs when tissues or nerves are inflamed. Pain can be caused by the chemotherapy and radiation therapy given before the transplant and by infection, medicine, mouth sores and skin problems.
Pain medicines and other therapies, such as relaxation or visualization, are used to help relieve pain. The healthcare team will help prevent and manage your pain.
Kidney problems can happen when the kidneys are damaged by chemotherapy drugs given before the transplant, by antibiotic therapy or by medicine used to suppress the immune system. Sometimes kidney problems become so serious that they can lead to kidney failure, which is a long-term problem.
To prevent kidney problems after a transplant or to treat kidney problems that happen, your healthcare team may limit the amount of fluids you drink and change some of your medicines. The healthcare team will closely check the amount of fluids you take in and put out as urine. They will take measures to prevent and reduce damage to the kidneys as much as possible during treatment.
Lung problems can happen when the lungs are damaged by the chemotherapy and radiation treatments given before the transplant, by infection or by drinking too much fluid after the transplant. Lung problems are common in people with GVHD and include the following:
The healthcare team will check you with chest x-rays and lung function tests. You may be given medicines to prevent infection after the transplant or to treat lung problems if they develop.
Heart problems are not common after a stem cell transplant but they can happen. Certain chemotherapy drugs given before the transplant can cause the heart not to work as well. They can also cause the tissue around the heart to become inflamed (called pericarditis).
A multigated acquisition (MUGA) scan to check how well your heart is working and assess any damage to the heart muscle is often done before chemotherapy is given. Chemotherapy drugs that are less damaging to the heart may be used before a stem cell transplant. Medicines can be used to treat heart problems that develop after a transplant.
The central nervous system (CNS) is made up of the brain and spinal cord. Brain tissue can be damaged by radiation treatments given before a stem cell transplant, by chronic GVHD, by infection or by a return of the cancer.
CNS problems can develop months or years after a stem cell transplant. CNS problems can include damage to the brain that results in problems with mental (cognitive) function. Other CNS problems include:
Report changes in your mental function to the healthcare team. You may see a neurologist and have therapy to help with these changes.
Eye problems usually develop a year after a stem cell transplant, but they can also happen several years later. Eye problems can happen if total body irradiation is given before a stem cell transplant. Chemotherapy and steroids may also increase the chance of developing eye problems.
The most common eye problem is cataracts. A cataract clouds the lens of the eye and can cause vision loss. You will be encouraged to have regular eye exams and report any vision changes. Cataracts are removed with surgery.
Another eye problem is ocular GVHD. It causes eye dryness with a gritty or sandy feeling. Ocular GVHD is treated with eye drops for comfort and to help the eyes produce tears. You may also be given medicine to prevent infection.
Bladder problems can happen when chemotherapy and radiation treatments given before the transplant scar the bladder wall. This can lead to frequent urination, blood in the urine and bladder spasms. Drugs that suppress the immune system can cause recurring bladder infections. You may be given medicines to decrease bladder spasms and treat infections. You will be encouraged to drink extra fluids.
The risk of developing thyroid problems is quite high when total body irradiation is used before a stem cell transplant. Hypothyroidism is the most common thyroid problem. This is where the thyroid does not make enough thyroid hormone. Symptoms of hypothyroidism include fatigue, weight gain, hair loss, brittle nails, dry skin and feeling cold.
For adults, thyroid function may be checked each year after a stem cell transplant. Some people may need thyroid hormone replacement therapy if the thyroid doesnt make enough thyroid hormone.
If children do not have enough thyroid hormone, it slows their physical and mental development. It usually develops a few years after treatment and can become a long-term problem. The thyroid function will be checked often. Some children may need thyroid hormone replacement every day to regulate the thyroid gland.
In children, total body irradiation can cause long-term developmental and growth delays. This can happen because radiation to the head affects the hypothalamus in the brain. The hypothalamus controls the release of growth hormones. Low levels of growth hormones will result in shorter height, shortened limbs and less overall physical development. Steroid medicines and GVHD can also affect growth. Treatment with growth hormones may be needed.
Fertility problems can happen because of chemotherapy or radiation therapy given before a stem cell transplant. When the reproductive organs (gonads) stop working, it is called gonadal dysfunction.
Children receiving treatment, especially those close to or during puberty, have the greatest chance of having long-term or permanent gonadal dysfunction, called gonadal failure. Children treated before puberty have fewer problems with reproductive organ function and fertility.
Most women who have a stem cell transplant will experience treatment-induced menopause. Men and women may regain gonadal functioning and fertility, but gonadal dysfunction may become permanent and cause infertility.
Hormone replacement therapy may be given for gonadal dysfunction.
Talk to your healthcare team about fertility problems. They can suggest ways to help women cope with symptoms of menopause. They can also provide information about ways you can preserve your fertility. Women may choose to freeze and store fertilized eggs (embryos) to be implanted after the transplant and recovery. Men may choose to freeze and store their sperm for future use.
Liver problems that can develop include veno-occlusive disease (VOD), graft-versus-host disease, infection or damage due to the medicines given before the transplant. Treatment is supportive and includes medicines for VOD, infection and pain. If kidney function is also affected, treatment includes limiting the amount of fluids you drink and changing some medicines.
Graft-versus-host disease is the most common cause of late oral and dental problems. Symptoms range from mild tenderness of the mouth, throat, esophagus and stomach to severe pain. Decreased saliva production results in tooth decay (cavities). Infections can also contribute to oral problems.
Mouth rinses, steroid dental pastes and medicines are used to treat oral and dental problems. You will be taught about careful and thorough care of your teeth and mouth. You will be encouraged to have regular visits to your dentist. You may be given fluoride treatments to help prevent cavities.
Primary graft failure means that transplanted stem cells have not started making new blood cells in the first 3 to 4 weeks after the transplant. Treatment for primary graft failure is a second stem cell transplant.
Secondary graft failure happens after new blood cells start appearing. Treatment includes a combination of growth factors such as erythropoietin and G-CSF. If an allogeneic transplant has been done, medicines to suppress the immune system are stopped. Lymphocytes from the donor or a second transplant may be needed.
Graft rejection (stem cell rejection) happens if the body rejects the transplanted stem cells. This is more common in allogeneic transplants, especially when the donor is unrelated or less well matched. Graft rejection may be treated with growth factors. Sometimes a second transplant can be done.
Osteoporosis is a loss of bone density. It makes the bones weak. It can develop late after a stem cell transplant because of medicines, gonadal dysfunction or lack of physical activity. Treatment includes taking extra vitamin D and calcium. Medicines called bisphosphonates may be given for severe osteoporosis. Women who have treatment-induced menopause may consider hormone replacement therapy to keep bones from becoming weaker.
Quality of life can be greatly affected by the problems caused by the transplant, the long-term side effects and the medicines needed to treat some of the long-term effects.
Some factors that can affect quality of life include depression, anxiety and changes in body image. Relationships with your family and friends can be affected by the stress of having cancer and getting a stem cell transplant for cancer. Also, the duration of the transplant and the long time it takes to recover may make you feel socially isolated.
Transplant centres and hospitals often have plans of care that will improve quality of life, including education for you and your family. Counselling about your work, rehabilitation programs, support groups and psychological counselling may help decrease the negative effects on quality of life.
Other cancers can develop because of the amount of chemotherapy and radiation therapy given before the transplant.
The chance of getting a second cancer increases over time. Doctors will check for a second cancer at all follow-up appointments.
Read the rest here:
Side effects of a stem cell transplant - Canadian Cancer ...
- BIORESTORATIVE THERAPIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K) - Marketscreener.com - March 29th, 2023
- Induced Pluripotent Stem Cell for the Study and Treatment of ... - Hindawi - December 3rd, 2022
- What Happens When Everyone Realises We Can Live Much Longer? We May Find Out As Soon As 2025 - Forbes - December 3rd, 2022
- INTERNATIONAL STEM CELL CORP Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com - November 17th, 2022
- 3D Cell Culture Market stands at revenue of US$ 1.15 Bn in 2022, and is predicted to surge at a CAGR of 9.8% to hit worth of US$ 2.67 Bn during... - November 17th, 2022
- YUBO INTERNATIONAL BIOTECH LTD Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com - November 17th, 2022
- ACTINIUM PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION (form 10-Q) - Marketscreener.com - November 17th, 2022
- Top 10 Best Stem Cell Supplement Brands - Healthtrends - June 26th, 2022
- How Does Stem Cell Therapy Work and What Are the Risks? | ISCRM - June 26th, 2022
- Stem Cell Wellness Kit - June 26th, 2022
- Kangstem Biotech withdraws trial application for stem cell-based osteoarthritis treatment - KBR - June 26th, 2022
- Global Human Embryonic Stem Cell Market to be Driven by the Rapid Technological Advancements in the Forecast Period of 2022-2027 Designer Women -... - June 26th, 2022
- Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the... - June 26th, 2022
- Efficient terminal erythroid differentiation requires the APC/C cofactor Cdh1 to limit replicative stress in erythroblasts | Scientific Reports -... - June 26th, 2022
- Propanc Biopharma's CSO Hails Dostarlimab's Impressive Results Whilst Acknowledging More Work to Be Done in the Fight Against Cancer - Business Wire - June 26th, 2022
- Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including... - June 26th, 2022
- 10 Years of Immunotherapy: Advances, Innovations, and Better Patient Outcomes - Targeted Oncology - June 26th, 2022
- Embryonic Stem Cell Research: An Ethical Dilemma - January 30th, 2022
- Skeletal Muscle Cell Induction from Pluripotent Stem Cells - January 30th, 2022
- mRNA COVID-19 Vaccine Effectiveness in the Immunocompromised - Medscape - January 30th, 2022
- MaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of Phase 1b CIMON Study - Business... - January 30th, 2022
- European Commission Approves Merck's KEYTRUDA (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following... - January 30th, 2022
- Targeted Therapy Innovator Foresees New Paradigms in Breast Cancer - OncLive - January 30th, 2022
- Global Circulating Tumor Cells (CTC) Market Growing Demand, Future Trends, Competitive Regions and Forecast 2021 to 2027 The Oxford Spokesman - The... - January 30th, 2022
- Adipose derived mesenchymal stem cell secretome formulation as a biotherapeutic to inhibit growth of drug resistant triple negative breast cancer |... - December 8th, 2021
- All at-risk TN-bound travellers test Covid negative - The New Indian Express - December 8th, 2021
- Good Stocks To Invest In Right Now? 4 Health Care Stocks To Check Out - FW Business - December 8th, 2021
- Pandemic lockdown declined emotional well-being for adults with hearing, vision loss: Study - ETHealthworld.com - December 8th, 2021
- Impact of microbial contamination of haematopoietic stem cells on post-transplant outcomes: A retrospective study from tertiary care centre in India -... - August 17th, 2021
- Longeveron: Time to Buy the Di - GuruFocus.com - August 17th, 2021
- The latest on the Covid-19 pandemic in the US: Live updates - CNN - August 17th, 2021
- How this Holocaust refugee beat Covid-19 against all odds J. - The Jewish News of Northern California - August 17th, 2021
- Trade-offs among transport, support, and storage in xylem from shrubs in a semiarid chaparral environment tested with structural equation modeling -... - August 17th, 2021
- Oklahoma 10-year-old in remission after being diagnosed with rare form of leukemia 2 years ago - KFOR Oklahoma City - July 21st, 2021
- Covid: There's a serious problem with how we are testing people for the virus Neale Hanvey MP - The Scotsman - July 21st, 2021
- Profilin 1 Protein and Its Implications for Cancers - Cancer Network - July 21st, 2021
- Homing Technology Delivers Therapy to Cancerous Bone - The Scientist - July 21st, 2021
- Developmental Interest in Allogeneic PlacentaDerived Cell Therapies Expands - OncLive - July 21st, 2021
- Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches - DocWire News - July 21st, 2021
- The World's First Lab-Grown Foie Gras Could Solve This Major Concern - Mashed - July 21st, 2021
- KEYTRUDA (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free... - July 21st, 2021
- Human Mesenchymal Stem Cells (hMSC) Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The Bisouv... - March 3rd, 2021
- [Full text] An Update on the Molecular Pathology of Metaplastic Breast Cancer | BCTT - Dove Medical Press - March 3rd, 2021
- 4D Pharma Appointments Paul Maier to the Board as Non-Executive Director - Business Wire - March 3rd, 2021
- Investigative Interventions Gain Ground in GVHD - OncLive - March 3rd, 2021
- Combination Regimens for Multiple Myeloma Show Efficacy in the Transplant-Ineligible Population, According to Dingli - Targeted Oncology - March 3rd, 2021
- Martin Makes Sense of the Rapidly Evolving MCL Treatment Paradigm - OncLive - March 3rd, 2021
- Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment - BioSpace - March 3rd, 2021
- Health Matters; Inflammation with Dr. Baumgartner [PODCAST] - WJON News - February 14th, 2021
- G1 Therapeutics gains first FDA nod with myelopreservation therapy Cosela | 2021-02-12 - BioWorld Online - February 14th, 2021
- Kris Gopalakrishnan on innovation - Fortune India - February 14th, 2021
- Change is coming, and at an ever-accelerating pace - Al Jazeera English - January 12th, 2021
- MCL Landscape Adapts to Changes After CAR T-Cell Therapy Approval - OncLive - January 9th, 2021
- 5 questions facing gene therapy in 2021 - BioPharma Dive - January 9th, 2021
- RNA molecules are masters of their own destiny - MIT News - January 9th, 2021
- Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Industry Analysis and Forecast (2019-2026): By indication type, treatment type,... - January 9th, 2021
- Harpoon Therapeutics : Clin Cancer Res 2021; OnlineFirst version Jan 6, 2021 - Marketscreener.com - January 9th, 2021
- Synthetic lethality across normal tissues is strongly associated with cancer risk, onset, and tumor suppressor specificity - Science Advances - January 5th, 2021
- Versiti Blood Centers and Noodles & Company Serve Up Thanks to Blood Donors - PRNewswire - January 5th, 2021
- January 2021: 2020 Papers of the Year - Environmental Factor Newsletter - January 5th, 2021
- Ozone in the air is bad for birds - Massive Science - January 5th, 2021
- How good are the COVID-19 vaccines? - Massive Science - January 5th, 2021
- Stem cells from cord blood can now be used across many conditions: Mayur Abhaya, MD & CEO, LifeCell Internat.. - ETHealthworld.com - December 28th, 2020
- Allogeneic SCT Benefits Children and Adolescents With Relapsed Anaplastic Large Cell Lymphoma - OncLive - December 28th, 2020
- CalvinAyre.com's most read life stories of 2020 - CalvinAyre.com - December 28th, 2020
- Coronavirus | Over 6,000 travellers from U.K. traced across States - The Hindu - December 28th, 2020
- Exosomes act as messengers and decoys to save healthy cells from viral infection - Massive Science - December 28th, 2020
- Celtics adjust to two-game series designed to reduce team travel - The Boston Globe - December 28th, 2020
- Experts Reflect on Most Impactful FDA Moves of 2020 in Solid Tumors, Hematologic Malignancies - Targeted Oncology - December 28th, 2020
- FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix (leronlimab) Following Full Enrollment in CytoDyn's Phase 3 Trial... - December 28th, 2020
- Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145... - December 12th, 2020
- Daratumumab Regimen Shows Promise in Transplant-Eligible Patients With Newly Diagnosed Myeloma - Targeted Oncology - December 12th, 2020
- HSCT Found Potentially Curative for Some T-Cell Lymphoma Patients - Cancer Therapy Advisor - December 12th, 2020
- Researchers Trace the Origin of Blood Cancer to Early Childhood, Decades before Diagnosis - Yahoo Finance - December 12th, 2020
- ALLO-715, Off-the-Shelf CAR T-Cell Therapy, Produces Early Promise in Multiple Myeloma - Cancer Network - December 12th, 2020
- BeiGene Announces the Approval in China of BLINCYTO (Blinatumomab) for Injection for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute... - December 12th, 2020
- Flintshire youngster goes the extra mile to raise funds for Lymphoma Action | The Leader - LeaderLive - December 12th, 2020
- Meat-Tech Agrees to Acquire Cultured Fat Pioneer 'Peace of Meat' - PRNewswire - December 12th, 2020
- Stem Cell Manufacturing Market Size, Overview with Detailed Analysis, Competitive landscape, Forecast to 2027 - Cheshire Media - December 12th, 2020
- Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American... - December 12th, 2020